Author:
Fabes Jez,Stanworth Simon
Publisher
Springer International Publishing
Reference161 articles.
1. Fabes J, Barker G, Simons G, Curry N, Brunskill SJ, Doree C, Lin Y, McKechnie S, Stanworth S. Pro‐coagulant haemostatic factors for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev. 2013;(7):CD010649. https://doi.org/10.1002/14651858.CD010649 .
2. Organisation WH. 20th WHO Model List of Essential Medicines. In, 2017.
3. Committee JF. British National Formulary (online). London: BMJ Group and Pharmaceutical Press.. http://www.medicinescomplete.com . [Accessed on 20.2.2018].
4. McCormack PL. Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis. Drugs. 2012;72:585–617.
5. Shakur H, Roberts I, Bautista R, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010;376:23–32.